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N
anoparticles comprised of polymers or
lipids can be used to encapsulate biologi-
cal or small molecule active pharmaceuti-
cal ingredients (APIs) for drug delivery. This
approach offers a number of advantages over tra-
ditional drug formulations, principally that the API
is protected from harsh extracellular environmen-
tal conditions in vivo, allowing delivery of the
intact API into the target tissues, cells and sub-cel-
lular compartments, while shielding it from chem-
ical or enzymatic degradation. Correspondingly,
nanoparticles can be used to prevent highly toxic
APIs – such as the cytotoxic agents used in cancer
therapies – from causing off-target unwanted side-
effects.
Packaging the API within nanoparticles not only
shields the drug from the body, or vice versa, it also
effectively decouples the relationship between drug
structure and biological targeting. By ‘hiding’ the
drug in the nanoparticle, its properties are masked
from biological processes which dictate its in vivo
localisation. Varying the physical properties or
chemical structure of the nanoparticles, therefore,
allows more effective targeting without compro-
mising API structure or function. A number of
potential in vivo targeting strategies have been sug-
gested, including coupling the particles to antibod-
ies or other biologically-derived recognition ele-
ments, but the majority of nanomedicines currently
in development rely on adjusting the physicochem-
ical properties of the particles themselves.
Liposomes – spheres composed of phospholipid
bilayers which are used to encapsulate drugs – are
the forerunners in the nanomedicine arena, with
the first FDA-approved example, Doxil®, first
appearing in 1995. A major benefit of liposomes as
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exploring the past,
present and future
Nanoparticles, and liposomes in particular, are growing in popularity as drug
delivery vehicles for anti-cancer agents and inflammatory disease therapies, as
well as forming the basis of a new class of vaccines. They offer a number of
advantages in terms of stability, efficacy and off-target effects, but traditional
manufacturing methods are labour-intensive, hard to reproduce and difficult to
scale up. This has contributed to a widely-held perception in the
pharmaceutical industry that nanomedicines are far from clinically practical. A
new generation of microfluidic systems is helping to overcome these issues,
allowing the rapid development and seamless scale-up of novel nanoparticles.
This technology is transforming the development and manufacture of a range
of nanoparticle formulations from a hit-and-miss affair into a standardised
process, accelerating novel nanomedicines from the bench to the clinic.
drug delivery vehicles is that their properties are
almost completely independent of the API they are
being used to transport; they can be made to a
range of sizes or magnitudes of charge, and used
with hydrophobic or hydrophilic payloads, helping
to overcome the solubility issues associated with
the former.
At scales relevant to clinical and commercial
production, liposomes are generally formed by
nanoprecipitation, followed by multiple extrusion
or homogenisation steps to refine size. With nano-
precipitation, lipid components are dissolved in a
water-miscible solvent, then mixed with an aque-
ous buffer. The resulting changes in the polarity
cause the nanoparticle components to self-assem-
ble. This turbulent mixing approach is difficult to
control and challenging to reproduce precisely, as a
wide range of parameters – including the mixing
mechanism, temperature, pH, nanoparticle compo-
sition and shear forces – affect the self-assembly
process. Further processing steps, such as sonica-
tion, homogenisation or membrane extrusion, are
therefore required to ensure consistent sizing
across the particle population. These additional
processing steps are labour-intensive, suffer from
poor batch-to-batch reproducibility and are diffi-
cult to scale. This not only affects the efficacy of
liposomes as drug delivery vehicles – particle size
has a significant impact on biodistribution – but it
also makes it difficult to compare results, establish
trends or apply rational design principles during
development. Researchers developing liposomal
drug delivery vehicles therefore all face the same
challenges: developing a potent formulation, meet-
ing the reproducibility criteria of regulatory
authorities and achieving reliable scale-up for fur-
ther testing. 
Along comes microfluidics 
These issues have significantly impeded progress in
this promising area of drug formulation, as many
pharmaceutical developers are tentative in their
nanomedicine approaches due to a lack of in-house
expertise, a poor track record of success and a per-
ceived risk en route to market. This has created a
clear demand for rapid, flexible and controlled
mixing processes, enabling consistent nano-
medicine production that meets the joint pressures
of short development timelines and ever-increasing
regulatory considerations. 
Laminar flow microfluidics is now emerging as
the potential solution to these challenges. Under
laminar flow, two fluid streams entering a
microfluidic channel appear as separate adjacent
streams, despite being miscible, before slowly dif-
fusing together. This process is both reproducible
and well-controlled, however, rapid mixing is cru-
cial to achieving small, uniform particles. There
are two microfluidic designs in particular that
promote rapid mixing and are already commonly
used in nanomedicine formulation: hydrodynamic
flow focusing and chaotic advection. Flow focus-
ing has been used predominantly to formulate
polymeric nanoparticles by entrapping hydropho-
bic small molecules, although there have also
been some examples of its use with nucleic acid
formulations. In contrast, chaotic advection has
been broadly adopted, largely because it can
Microfluidic LNP formulation.
Nucleic acids in buffer (left)
and LNP precursors in solvent
(right) are injected into the
two inlets of a microfluidic
cartridge, where they are
mixed in a controlled fashion.
LNPs of different sizes can be
produced by varying the
relative and total flow rates
(far right)
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achieve higher flow rates (two orders of magni-
tude greater than flow focusing), and because
there are commercially available systems based on
this method designed specifically for the develop-
ment and production of nanomedicines. ‘Ready-
made’ systems like this remove the burden of
instrument and chip design from drug develop-
ment labs, overcoming the ‘knowledge gap’ tradi-
tionally associated with microfluidics and allow-
ing researchers to concentrate their efforts on the
development of effective APIs. 
No longer a black art
The highly-predictable mixing offered by these
systems ensures the rapid, controlled production
of a variety of nanoparticles. Optimising the
geometry of the microfluidic chips maximises the
interface between the fluid phases, allowing pre-
cisely controlled mixing in milliseconds in nano-
litre reaction volumes. Component mixing occurs
faster than nanoparticle self-assembly, preventing
sub-optimal mixing and heterogeneous precipita-
tion, and the low energy conditions required are
ideal for biologics. This standardisation of pro-
cessing allows the production of nanoparticles
with carefully defined characteristics, including
chemical compositions, concentrations and
drug/excipient ratios. Crucially, this approach
also provides a clear route to scaling up produc-
tion, as multiple identical chips can be run in par-
allel. This allows throughput to be increased to
meet the requirements of each phase of the drug
development workflow, without changing the
reaction conditions. 
The flexibility and reproducibility of these auto-
mated microfluidics platforms has revolutionised
the way researchers are approaching nanoparticle
development. By minimising batch-to-batch and
operator-to-operator variability, these systems
allow accurate assessment of how changes in pro-
cessing variables – drug and excipient concentra-
tions, flow rates and mixing ratios – affect the
structure and composition of the resulting
nanoparticles, including average particle diameter,
polydispersity (inhomogeneity) and drug encapsu-
lation efficiency. This reproducibility means it is
now possible to use a Design of Experiment (DoE)
approach to rapidly assess and define the best
parameters for robust manufacturing of any given
nanoparticle, then screen lead formulations for the
desired biological activity. And, because the final
product is available in minutes, instead of several
hours using conventional techniques, this helps to
accelerate development timelines. 
One of the biggest advantages of this approach
is that the structure and behaviour of the resulting
nanoparticles can be predicted according to the
processing parameters and particle composition.
Data generated by both the University of
Strathclyde and Precision NanoSystems – for lipo-
somes and polymeric particles respectively – illus-
trates that processing parameters or particle com-
positions can be fine-tuned to achieve the desired
particles, enabling a more structured approach to
nanomedicine research. By mapping out an
approximate design space around the key process
parameters for any given particle type and formu-
lation, research groups can now quickly and easily
screen and optimise their particles, allowing them
to concentrate on in vivo drug function instead of
particle manufacture.
Putting it to use
Due to the relative cost of nanomedicine formula-
tions in comparison to simple dosage forms, such
as pressed tablets, the areas most likely to benefit
Multiple microfluidic devices
can perform the same
operation in parallel to
increase throughput
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from this approach are those where current strate-
gies are either ineffective – due to poor in vivo sta-
bility or bioavailability, for example – or where
they cause significant off-target effects, such as
anti-cancer agents. Liposome encapsulation of can-
cer therapeutics is already gaining some traction as
this limits off-target cytotoxicity, and the ‘leaky’
vasculature commonly associated with tumours
means that nanoparticles below around 100nm
passively aggregate in these sites, where they break
down and release their payload.
Another strategy currently under investigation is
the use of liposomes as carriers for subunit vac-
cines, in an effort to replace some live attenuated
vaccines. For example, the only current tuberculo-
sis (TB) vaccine is the BCG, which is very effective
in developed countries, but is less effective in
regions such as sub-Saharan Africa where there is
high incidence of TB. This is because the vaccine is
ineffective if patients have already been pre-
exposed to the pathogen, and it is not suitable for
immunocompromised patients – such as HIV posi-
tive individuals – as there is a small risk of the bac-
teria being reactivated. In contrast, subunit vac-
cines offer improved safety profiles by not expos-
ing the patient to whole pathogen, attenuated or
otherwise. Designed to present a single antigen
– often a single pathogen protein – to the immune
system, this avoids many of the issues associated
with live attenuated vaccines, but most subunit
vaccines suffer from poor efficacy, as they do not
generate a strong immune response. By putting
these antigen groups on to the surface of lipo-
somes, the immune response can be boosted with-
out compromising the safety of the vaccine. 
This approach could also lead to the develop-
ment of a generic particle which could be used to
accelerate the development and manufacture of
new subunit vaccines to counter global health
crises. For example, during the recent H1N1
influenza outbreak, by the time a vaccine had been
produced, the outbreak was already abating. If you
project this on to a more significant pandemic,
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Illustrated process of nucleic acid LNP formation. 
1) Ionisable lipids (blue) become positively charged at
acidic pH and electrostatically interact with negatively-
charged nucleic acids (green) to form the particle core.
2) Other lipid species (purple and yellow) assemble
around the nascent LNP core as water displaces ethanol
and increases the polarity of the environment. 3) Lipids
conjugated to polyethylene glycol assemble slowest,
forming a protective coating. 4) Cross-section of the
fully-formed LNP with nucleic acids encapsulated
completely within the particle
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then a vaccine would only be available to innocu-
late the survivors, which is futile. If, instead, a
generic carrier particle was already available and
ready for manufacture, then efforts could concen-
trate on identifying and producing the correct anti-
gen, speeding up the entire process. While the
mutation rate of the HIV virus may present a sig-
nificant challenge to this strategy, it could be effec-
tive against other viruses of international concern –
such as Zika – providing a rapid vaccine develop-
ment platform.
Summary 
The commercial availability of microfluidic plat-
forms aimed specifically at drug formulation is
helping to lower the barriers to nanomedicine
research. Implementation of this technology elimi-
nates the need for in-house microfluidics expertise
and extensive process development, helping to
accelerate research and development timelines and
providing a clear roadmap from early research to
end product. By working with these technologies,
researchers can spend their time designing and
planning their experiments, solving problems and
asking the big questions, rather than making
nanoparticles.                                                DDW
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